Rodríguez-Pardo, DolorsDel Toro, María DoloresGuío-Carrión, LauraEscudero-Sánchez, RosaFernández-Sampedro, MartaGarcía-Viejo, Miguel ÁngelVelasco-Arribas, MaríaSoldevila-Boixader, LauraFemenias, MagdalenaIribarren, José AntonioPulido-Garcia, María Del CarmenNavarro, María DoloresLung, MayliCorona, Pablo SAlmirante, BenitoPigrau, Carles2023-02-092023-02-092021-04-16http://hdl.handle.net/10668/17592To evaluate preoperative asymptomatic bacteriuria (ASB) treatment to reduce early-periprosthetic joint infections (early-PJIs) after hip hemiarthroplasty (HHA) for fracture. Open-label, multicenter RCT comparing fosfomycin-trometamol versus no intervention with a parallel follow-up cohort without ASB. early-PJI after HHA. Five hundred ninety-four patients enrolled (mean age 84.3); 152(25%) with ASB (77 treated with fosfomycin-trometamol/75 controls) and 442(75%) without. Despite the study closed without the intended sample size, ASB was not predictive of early-PJI (OR: 1.06 [95%CI: 0.33-3.38]), and its treatment did not modify early-PJI incidence (OR: 1.03 [95%CI: 0.15-7.10]). Neither preoperative ASB nor its treatment appears to be risk factors of early-PJI after HHA. ClinicalTrials.gov Identifier: Eudra CT 2016-001108-47.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Asymptomatic bacteriuriaEarly-periprosthetic joint infectionFosfomycin-trometamolHip hemiarthroplastyAgedAged, 80 and overAnti-Bacterial AgentsArthroplasty, Replacement, HipAsymptomatic InfectionsBacteriuriaFemaleFosfomycinHumansJoint DiseasesMaleProsthesis-Related InfectionsTromethamineresearch article33864153open access10.1007/s10096-021-04241-21435-4373https://www.researchsquare.com/article/rs-203528/v1.pdf?c=1631892207000